Cargando…

Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: Real‐world data from a multicentric European cohort

In patients with human epidermal growth factor receptor 2 positive (HER2+) breast cancer, leptomeningeal metastases (LM) are a rare but often a fatal clinical scenario. In this multicentric study, clinical and pathologic characteristics of patients with HER2+ breast cancer developing LM were describ...

Descripción completa

Detalles Bibliográficos
Autores principales: Ratosa, Ivica, Dobnikar, Nika, Bottosso, Michele, Dieci, Maria Vittoria, Jacot, William, Pouderoux, Stéphane, Ribnikar, Domen, Sinoquet, Léa, Guarneri, Valentina, Znidaric, Tanja, Darlix, Amélie, Griguolo, Gaia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540903/
https://www.ncbi.nlm.nih.gov/pubmed/35666525
http://dx.doi.org/10.1002/ijc.34135
_version_ 1784803806703255552
author Ratosa, Ivica
Dobnikar, Nika
Bottosso, Michele
Dieci, Maria Vittoria
Jacot, William
Pouderoux, Stéphane
Ribnikar, Domen
Sinoquet, Léa
Guarneri, Valentina
Znidaric, Tanja
Darlix, Amélie
Griguolo, Gaia
author_facet Ratosa, Ivica
Dobnikar, Nika
Bottosso, Michele
Dieci, Maria Vittoria
Jacot, William
Pouderoux, Stéphane
Ribnikar, Domen
Sinoquet, Léa
Guarneri, Valentina
Znidaric, Tanja
Darlix, Amélie
Griguolo, Gaia
author_sort Ratosa, Ivica
collection PubMed
description In patients with human epidermal growth factor receptor 2 positive (HER2+) breast cancer, leptomeningeal metastases (LM) are a rare but often a fatal clinical scenario. In this multicentric study, clinical and pathologic characteristics of patients with HER2+ breast cancer developing LM were described, as well as survival outcomes. Data were gathered retrospectively from medical records of 82 patients with advanced HER2+ breast cancer and LM treated between August 2005 and July 2020. Following LM diagnosis, 79 (96.3%) patients received at least one line of anti‐HER2 therapy, 25 (30.5%) patients received intrathecal therapy and 58 (70.7%) patients received radiotherapy. Overall survival (OS) was 8.3 months (95% confidence interval [CI] 5.7‐11), 1‐year OS was 42%, and 2‐year OS was 21%. At univariate analysis, patients who were treated after 2010, had better Karnofsky performance status, were free of neurological symptoms, had better prognostic, received chemotherapy (OS difference 9.4 months, P = .024), or monoclonal antibodies (trastuzumab ± pertuzumab; OS difference 6.1 months; P = .013) after LM diagnosis, had a statistically significantly longer OS. Presence of neurological symptoms (hazard ratio 3.32, 95% CI 1.26‐8.73; P = .015) and not having received radiotherapy (hazard ratio 2.02, 95% CI 1.09‐3.72; P = .024) were all associated with poorer OS at multivariate analysis. To summarize, not having neurological symptoms and receiving RT at LM diagnosis were associated with prolonged OS in our cohort. Survival seemed to be prolonged with multimodality treatment, which included targeted therapy, chemotherapy, and RT to the LM sites.
format Online
Article
Text
id pubmed-9540903
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-95409032022-10-14 Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: Real‐world data from a multicentric European cohort Ratosa, Ivica Dobnikar, Nika Bottosso, Michele Dieci, Maria Vittoria Jacot, William Pouderoux, Stéphane Ribnikar, Domen Sinoquet, Léa Guarneri, Valentina Znidaric, Tanja Darlix, Amélie Griguolo, Gaia Int J Cancer Cancer Therapy and Prevention In patients with human epidermal growth factor receptor 2 positive (HER2+) breast cancer, leptomeningeal metastases (LM) are a rare but often a fatal clinical scenario. In this multicentric study, clinical and pathologic characteristics of patients with HER2+ breast cancer developing LM were described, as well as survival outcomes. Data were gathered retrospectively from medical records of 82 patients with advanced HER2+ breast cancer and LM treated between August 2005 and July 2020. Following LM diagnosis, 79 (96.3%) patients received at least one line of anti‐HER2 therapy, 25 (30.5%) patients received intrathecal therapy and 58 (70.7%) patients received radiotherapy. Overall survival (OS) was 8.3 months (95% confidence interval [CI] 5.7‐11), 1‐year OS was 42%, and 2‐year OS was 21%. At univariate analysis, patients who were treated after 2010, had better Karnofsky performance status, were free of neurological symptoms, had better prognostic, received chemotherapy (OS difference 9.4 months, P = .024), or monoclonal antibodies (trastuzumab ± pertuzumab; OS difference 6.1 months; P = .013) after LM diagnosis, had a statistically significantly longer OS. Presence of neurological symptoms (hazard ratio 3.32, 95% CI 1.26‐8.73; P = .015) and not having received radiotherapy (hazard ratio 2.02, 95% CI 1.09‐3.72; P = .024) were all associated with poorer OS at multivariate analysis. To summarize, not having neurological symptoms and receiving RT at LM diagnosis were associated with prolonged OS in our cohort. Survival seemed to be prolonged with multimodality treatment, which included targeted therapy, chemotherapy, and RT to the LM sites. John Wiley & Sons, Inc. 2022-06-25 2022-10-15 /pmc/articles/PMC9540903/ /pubmed/35666525 http://dx.doi.org/10.1002/ijc.34135 Text en © 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Cancer Therapy and Prevention
Ratosa, Ivica
Dobnikar, Nika
Bottosso, Michele
Dieci, Maria Vittoria
Jacot, William
Pouderoux, Stéphane
Ribnikar, Domen
Sinoquet, Léa
Guarneri, Valentina
Znidaric, Tanja
Darlix, Amélie
Griguolo, Gaia
Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: Real‐world data from a multicentric European cohort
title Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: Real‐world data from a multicentric European cohort
title_full Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: Real‐world data from a multicentric European cohort
title_fullStr Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: Real‐world data from a multicentric European cohort
title_full_unstemmed Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: Real‐world data from a multicentric European cohort
title_short Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: Real‐world data from a multicentric European cohort
title_sort leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: real‐world data from a multicentric european cohort
topic Cancer Therapy and Prevention
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540903/
https://www.ncbi.nlm.nih.gov/pubmed/35666525
http://dx.doi.org/10.1002/ijc.34135
work_keys_str_mv AT ratosaivica leptomeningealmetastasesinpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerrealworlddatafromamulticentriceuropeancohort
AT dobnikarnika leptomeningealmetastasesinpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerrealworlddatafromamulticentriceuropeancohort
AT bottossomichele leptomeningealmetastasesinpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerrealworlddatafromamulticentriceuropeancohort
AT diecimariavittoria leptomeningealmetastasesinpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerrealworlddatafromamulticentriceuropeancohort
AT jacotwilliam leptomeningealmetastasesinpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerrealworlddatafromamulticentriceuropeancohort
AT pouderouxstephane leptomeningealmetastasesinpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerrealworlddatafromamulticentriceuropeancohort
AT ribnikardomen leptomeningealmetastasesinpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerrealworlddatafromamulticentriceuropeancohort
AT sinoquetlea leptomeningealmetastasesinpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerrealworlddatafromamulticentriceuropeancohort
AT guarnerivalentina leptomeningealmetastasesinpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerrealworlddatafromamulticentriceuropeancohort
AT znidarictanja leptomeningealmetastasesinpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerrealworlddatafromamulticentriceuropeancohort
AT darlixamelie leptomeningealmetastasesinpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerrealworlddatafromamulticentriceuropeancohort
AT griguologaia leptomeningealmetastasesinpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancerrealworlddatafromamulticentriceuropeancohort